Muscle Invasive Bladder Cancer (MIBC) (Oncology) - Drugs in Development, 2021SummaryMuscle Invasive Bladder Cancer (MIBC) (Oncology) - Drugs in Development, 2021 provides an overview of the Muscle Invasive Bladder Cancer (MIBC) pipeline landscape.The repo…
Thymic Carcinoma (Oncology) - Drugs in Development, 2021SummaryThymic Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Thymic Carcinoma pipeline landscape.The report provides comprehensive information on the therapeutics under…
Liver Cancer (Oncology) - Drugs in Development, 2021SummaryLiver Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Liver Cancer pipeline landscape.The report provides comprehensive information on the therapeutics under development…
Extrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021SummaryExtrahepatic Bile Duct Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Extrahepatic Bile Duct Cancer pipeline landscape.The report provides comprehensiv…
Vulvar Cancer (Oncology) - Drugs in Development, 2021SummaryVulvar Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Vulvar Cancer pipeline landscape.The report provides comprehensive information on the therapeutics under developm…
Transitional Cell Cancer (Urothelial Cell Cancer) (Oncology) - Drugs in Development, 2021SummaryTransitional Cell Cancer (Urothelial Cell Cancer) (Oncology) - Drugs in Development, 2021 provides an overview of the Transitional Cell Cancer (Urothelial Cell…
Malignant Glioma (Oncology) - Drugs in Development, 2021SummaryMalignant Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Glioma pipeline landscape.The report provides comprehensive information on the therapeutics under…
Burkitt Lymphoma (Oncology) - Drugs in Development, 2021SummaryBurkitt Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Burkitt Lymphoma pipeline landscape.The report provides comprehensive information on the therapeutics under…
T-Cell Leukemia (Oncology) - Drugs in Development, 2021SummaryT-Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the T-Cell Leukemia pipeline landscape.The report provides comprehensive information on the therapeutics under de…
この調査レポートは中国の分子診断学市場を分析・予測したRenub Researchの市場調査報告書です。OverviewMolecular diagnostics plays an important role in the identification of diseases and has gained more public & healthcare specialist attention than ever before…
英国スペンドエッジ(SpendEdge)の世界の医薬品中間体・API市場に関する調達市場情報レポートです。
About Drug Intermediates and APIs Market
Pharmaceutical ingredients are broadly classified into two product groups, namely, intermediates and APIs, which …
The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, thi…
The active pharmaceutical ingredients (API) market was valued at approximately USD 174.96 billion in 2020, and it is expected to reach USD 245.88 billion by 2026, registering a CAGR of nearly 5.84% during the forecast period, 2021-2026.
In 2020, the outb…
Real World Evidence/RWE Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Neurology), End User (Pharma, Medtech, Payers, Providers) Covid-19 Impact - Global Forecast to 2026
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs. The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions…